Robert Hancock

MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada.

Inimex Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of Innate Defense Regulators (IDRs). IDRs are novel drugs that selectively trigger the body's innate defenses, protecting against antibiotic-resistant infections and controlling inflammation. The company was founded in 2001 and is headquartered in Vancouver, Canada.

Center for Drug Research & Development operates as a drug development and commercialization company. The firm provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. The company was founded in 2007 and is headquartered in Vancouver, Canada.

Sepset Biosciences, Inc. is a molecular diagnostics company based in Vancouver, Canada, founded by Robert E. W. Hancock. The Canadian company is developing a first-in-class diagnostic assay for the very early and rapid diagnosis of severe sepsis. This novel diagnostic is based on the detection of a unique signature of severe sepsis based on the dysfunctional immune response rather than the presence of a pathogen. Sepsis causes the hospitalization of more than 49 million people around the world every year, including ~170,000 Canadians, and has a staggering 23-30%% mortality rate while leaving most survivors suffering from long-term, physical and physiological effects. The total cost of treating sepsis in the USA amounts to $24 billion per year.

Vocan Biotechnologies, Inc. operates as a genetic engineering and biosynthesis research firm. It develops proprietary fermentation system for the production of psilocybin API. The company was founded by Jan Burian and is headquartered in Victoria, Canada.

Asep Medical, Inc. invests in the healthcare sector. The private company is based in Victoria, Canada. and has subsidiaries in Canada. The CEO of the Canadian company is Rudy A. Mazzocchi.

Part of Asep Medical, Inc., ABT Innovations, Inc. manufactures peptide products for inflammatory medications. The company is based in Victoria, Canada. The Canadian company was founded in 2015 by Robert E. W. Hancock. The CEO is Rudy A. Mazzocchi. ABT Innovations was acquired by Asep Medical, Inc. on May 14, 2021 for $2.06 million.